Cypris Therapeutics Launches as Newest Ichor Life Sciences Portfolio Company, Secures Over $500k in Pre-Seed Funding
Summary
"The companys proprietary technology enables the synthesis and iteration of complex small molecule moieties that have been previously unattainable by researchers. Cypris can modify these natural molecules to improve their therapeutic properties and reduce undesired side effects. This synthetic chemistry innovation holds the potential to significantly improve the standard of care for patients that do not respond to existing treatments.Cypris Therapeutics has formed as the newest start-up in the portfolio of Ichor Life Sciences, a Syracuse-based contract research organization. Cypris will incubate at Ichors facilities and gain access to Ichors state-of-the-art equipment in addition to drug discovery and development expertise.Ichor CEO and Founder Kelsey Moody, PhD, MBA stated, "We see vast potential in Cypris Therapeutics technology not only as a promising opportunity to develop next generation oncology treatments, but as a platform for iterating natural products for other age-related indications where traditional medicinal chemistry approaches have been elusive.Cypris Therapeutics remains committed to its vision of delivering innovative cancer treatments that make a real difference in patients lives. As the company moves forward, it continues to seek additional funding and partnerships to support its ambitious goals.For more information or media inquiries about Cypris Therapeutics, contact info@cypristx.com.